Biomarkers of Mucinous Tumors of the Ovary

  title={Biomarkers of Mucinous Tumors of the Ovary},
  author={G. Samimi and L. Ozbun and Michael E. Johnson and S. Mok and M. Birrer},
  journal={Disease Markers},
  pages={389 - 396}
Goli Samimia,b, Laurent Ozbunb, Michael E. Johnsonc, Samuel C. Mokc and Michael J. Birrerb Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, MD 20892, USA Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA Laboratory of Gynecologic Oncology, Brigham and Women’s Hospital Harvard Medical School, Boston, MA 02115, USA 
Genetic Variation in TYMS in the One-Carbon Transfer Pathway Is Associated with Ovarian Carcinoma Types in the Ovarian Cancer Association Consortium
Biomarkers that distinguish ovarian carcinoma types are few, and TYMS rs495139 may provide a novel clue to type etiology, indicating the importance of accurate histopathologic classification. Expand
Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Differential analysis revealed the up-regulation of extracellular proteasomes in tumor interstitial fluid compared to the healthy control, and detection of proteasome 20S related proteins in TIF compared to IF from healthy tissue indicates that the 20S proteasom can have a role in the tumor microenvironment. Expand
Characterization of annexin A2 in chicken follicle development: Evidence for its involvement in angiogenesis.
This study found that ANXA2 mRNA expression increased during chicken ovary maturation and follicle development and overexpression resulted in increased vascular endothelial growth factor A (VEGFA) secretion and theca cell proliferation. Expand


Survival among women with borderline ovarian tumors and ovarian carcinoma
Comparison of the survival for women with LMP tumors staged as distant with women who have carcinoma may have important implications for diagnostic terminology and clinical management. Expand
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.
  • V. Hess, R. A'hern, +9 authors M. Gore
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
Patients with advanced mEOC have a poorer response to platinum-based first-line chemotherapy compared with patients with other histologic subtypes of EOC, and their survival is worse, and specific alternative therapeutic approaches should be sought. Expand
Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma.
It is suggested that certain benign serous or mucinous ovarian tumors have the potential for malignant transformation and removal of these tumors, particularly in postmenopausal women, should result in a subsequent reduction in the frequency of ovarian cancer. Expand
Update on early ovarian cancer and cancer developing in benign ovarian tumors
The clinicopathological features of early ovarian cancer and whether early diagnosis and treatment will result in a major improvement in prognosis are studied. Expand
Metastatic tumors in the ovary: a problem-oriented approach and review of the recent literature.
This subject is reviewed with a consideration of the various patterns and cell types encountered in these tumors, which include a variety of neoplasms originating in the gastrointestinal tract and its appendages that simulate closely primary ovarian endometrioid and mucinous tumors. Expand
k-ras Mutation May Be an Early Event in Mucinous Ovarian Tumorigenesis
The presence of a k-ras mutation in adjacent benign and borderline regions of a single OMT may suggest a progression in the development of OMTs from benign to borderline and grade 1 OMCs. Expand
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.
This model of carcinogenesis reconciles the relationship of borderline tumors to invasive carcinoma and provides a morphological and molecular framework for studies aimed at elucidating the pathogenesis of ovarian cancer. Expand
[Expression of the cdx2 gene in benign intestinal-type mucinous ovarian tumors].
The aim of this study is to detect cdx2 positivity, with evaluation of its characteristics and expression, in ovarian mucinous cistoadenomas and hypothesise a selective and specific correlation between cdx1 positivity and the intestinal type epithelial component of ovarian tumours. Expand
Mucinous tumors of the ovary: a review.
  • W. R. Hart
  • Medicine
  • International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • 2005
A high index of suspicion that a mucinous tumor is actually a metastasis from another organ is required by pathologists and gynecologists to prevent misdiagnosis of a metastatic neoplasm as a primary ovarian tumor. Expand
The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
  • G. Groisman, A. Meir, E. Sabo
  • Medicine, Biology
  • International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • 2004
Cdx2 is a highly sensitive (100%) marker for colonic carcinoma metastatic to the ovary and C dx2 is more specific than CK20 as it is not expressed by serous and endometrioid carcinomas; and a limited panel of Cdx2 and CK7 helps in distinguishing colonic cancerous tumours from primary ovarian serous, endometioid, and mucinous carcinomas. Expand